Replies to post #86237 on Biotech Values

[DewDiligence]

i think you have that backwards - gen2/3 do better than 1/4, and typically require shorter treatment periods (soc is 24 weeks for gen2/3, and may be even shorter than that depending on viral kinetics)

You’re correct, of course. I guess I need a stronger coffee (in preparation right now :- ) ). The point in my reply to iwfal that non-RVR patients in response based therapy still need 48 weeks of ifn is valid, however.

Hence, the main point of this thread still stands: ifn vendors cannot simply double their prices to offset a halving of the duration of treatment.